Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[haysaw]

I don't disagree wih that statement. I just don't agree that antbloc can be grouped in with 41000 compounds looking to enter the pharmaceutical radar. For instance, it already has a market, unlike almost every other fledgling biotech. The route they took is a blessing and a curse, a blessing because of the evidence of efficacy in mid-stage studies and thousands of users, and a curse because of the reputation of supplements in treating medical conditions. Until the transformation to a biotech takes hold, anatabine won't be considered a serious pharma prospect. Even still, the IP will have to be solid.

Re: the picture - what do you think?